

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Dendritic cell-directed lentivector-based HIV vaccines	<p>Mouse studies suggest that lentivector-based HIV vaccines targeted to dendritic cells (DCs) could help prevent HIV infection. In mice, a DC-targeting lentiviral vector encoding the HIV-1 Gag antigen triggered higher Gag-specific CD8⁺ and CD4⁺ T cell responses than empty vector and control buffer. Next steps include evaluating the vaccine in a nonhuman primate model of HIV and developing strategies to further enhance the immune response.</p> <p>SciBX 2(46); doi:10.1038/scibx.2009.1712 Published online Dec. 3, 2009</p>	<p>Patent application filed for this vaccine platform in infectious diseases and cancers; licensed to Immune Design Corp.</p>	<p>Dai, B. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Nov. 16, 2009; doi:10.1073/pnas.0911742106 Contact: Pin Wang, University of Southern California, Los Angeles, Calif. e-mail: pinwang@usc.edu Contact: David Baltimore, California Institute of Technology, Pasadena, Calif. e-mail: baltimo@caltech.edu</p>